MAS-HibVAC®

Haemophilus influenzae type b conjugate vaccine

Haemophilus influenzae type b conjugate vaccine is in the form of a uniform and sterile suspension of Haemophilus influenzae type b PRP conjugated with tetanus toxoid (Hib-TT).
MAS-HibVAC^® vaccine is produced using the most advanced technology in the world and under cGMP conditions and with the best quality at Masoon Daru Company.
MAS-HibVAC^® vaccine is supplied in a 3 ml glass vial in sterile and lyophilized form for intramuscular injection.
MAS-HibVAC^® vaccine contains Haemophilus influenzae type b PRP conjugated with tetanus toxoid (Hib-TT) as the active ingredient and aluminum phosphate as the adjuvant.

Haemophilus influenzae type b is one of the important causative agents of dangerous infectious diseases in children. In developing countries, pneumonia and meningitis caused by Hib are common in children under 12 months of age, and meningitis caused by the bacteria is a leading cause of death. With the use of Hib conjugate vaccine in industrialized countries, diseases caused by this bacterium have been brought under control. Haemophilus influenzae type b conjugate vaccine is used for routine active immunization of young people aged 2 to 59 months against diseases caused by Haemophilus influenzae type b.

The use of MAS-HibVAC^® vaccine is the only way to prevent dangerous infectious diseases caused by Hib bacteria in children. Haemophilus influenzae type b conjugate vaccine is the only domestically produced Hib vaccine in the country, which has the following important advantages:

Effective and safe immunization against various infectious diseases caused by Hib bacteria
Creating rapid and strong immunity against diseases
High product quality in accordance with the latest international standards